Elicio Therapeutics Reports Q3 2026 Financial Results
Elicio Therapeutics reported Q3 2026 financial results, highlighting a 49% reduction in disease recurrence risk in cancer patients and providing updates on clinical development, specifically the Phase 3 adjuvant PDAC strategy and a new Phase 1 trial.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed